ArticleThe AAPS journal2026
In-depth Evaluation of the Olink Target 48 Cytokine Panel: Inter-Laboratory Evaluation of Performance and Reliability for Biomarker Studies in Oncology.
Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olink Target 48 Cytokine (Thermo Fisher Scientific) is a biomarker panel and assay kit frequently used to characterize the pharmacodynamic effects of novel therapeutics and predict treatment outcomes. We have assessed assay performance across four commercial laboratories to determine the consistency of results. Overall reliability of individual biomarkers and the performance of controls were also assessed, and data were used for an exploratory assessment of differential biomarker expression in patients with head and neck cancer or lung cancer, relative to healthy donors. Reproducibility between operators was found to be good for three of the four laboratories, although the median coefficient of variation between operators for laboratory 4 was above the threshold of acceptability (30%) in the first half of the study. Performance across serial dilutions was also good for all laboratories except laboratory 2. Overall, data were statistically concordant for all laboratories except laboratory 4. Olink sample and calibrator controls performed well, and 43 of the 45 biomarkers in the panel were found to have good or moderate reliability. In total, 21 biomarkers were found to be upregulated or downregulated in patients with cancer relative to healthy donors. This comprehensive evaluation supports the use of Olink Target 48 Cytokine for use in biomarker studies and clinical applications, and highlights the need for standardization in sample handling and assay execution across providers.
Indexed as
Identifiers
41775992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.